Development of 177Lu-phytate Complex for Radiosynovectomy

Document Type : Original Article


1 Radiopharmaceutical Research and Development Lab, Nuclear Science and Technology Research Institute (NSTRI), Tehran, Iran, P.O.Box:14395-836 2 Faculty of Energy Engineering and Physics, Amirkabir University of Technology. Tehran, Iran

2 Radiopharmaceutical Research and Development Lab, Nuclear Science and Technology Research Institute (NSTRI), Tehran, Iran, P.O.Box:14395-836

3 Radiation Application Group, Faculty of Nuclear Engineering, Shahid Beheshti University, Tehran, Iran


Objective(s): In this work a new possible agent for radiosynovectomy has been targeted for articular pain palliation.
Materials and Methods: Lu-177 of 2.6-3 GBq/mg specific activity was obtained by irradiation of natural Lu2O3 sample with thermal neutron flux of 4 × 1013 The product was converted into chloride form which was further used for labeling of 177Lu-phytate complex and checked using ITLC (MeOH: H2O: acetic acid, 4: 4: 2, as mobile phase). The complex stability and viscosity were checked in the final solution up to seven days. The prepared complex solution (100 µCi/100 µl) was injected intra-articularly to male rat knee joint. Leakage of radioactivity from injection site and its distribution in organs were investigated up to seven days.
Results: The complex was successfully prepared with high radiochemical purity (>99.9 %). Approximately, the whole injected dose has remained in injection site seven days after injection.
Conclusion: The complex was proved to be a feasible agent for cavital radiotherapy in oncology and rheumatology


1. European Association of Nuclear Medicine (EANM)
Procedure guidelines for radiosynovectomy, Guidelines issued date: October 4, 2002.
2. Kropácek M, Melichar F, Henková K, Konopková M. Preparation of Holmium-166 Labelled Macroaggregates for radionuclide synovectomy. Nucl Med Rev Cent East Eur. 2003; 6:1-4.
3. Suzuki YS, Momose Y, Higashi N, Shigematsu A, Park KB, Kim YM, et al. Biodistribution and kinetics of holmium-166-phytate complex (DW-166HC) in rats and mice, J Nucl Med 1998; 39:2161–2166.
4. Bodei L, Ferone D, Grana CM, Cremonesi M, Signore A, Dierckx RA, Paganelli G. Peptide receptor therapies in neuroendocrine tumors. J Endocrinol Invest. 2009; 32:360-369.
5. Michel RB, Andrews PM, Rosario AV, Goldenberg DM, Mattes MJ. 177Lu-antibody conjugates for single-cell kill of B-lymphoma cells in vitro and for therapy of micrometastases in vivo. Nucl Med Biol. 2005; 32:269-278.
6. Breitz H, Wendt R, Stabin M, Bouchet L, Wessels B. Dosimetry of high dose skeletal targeted radiotherapy (STR) with 177Lu-DOTMP. Cancer Biother Radiopharm. 2003; 18: 225-30.
7. Chakraborty S, Das T, Sarma HD, Venkatesh M, Banerjee S. Preparation and preliminary studies on 177Lu-labeled hydroxyapatite particles for possible use in the therapy of liver cancer. Nucl Med Biol 2008; 35:589-97.
9. Manual for reactor produced radioisotopes, IAEA, Vienna, 2003, IAEA- TECDOC-1340, ISBN 92–0–101103–2, ISSN 1011–4289, © IAEA, 2003, pp.121-123, Printed by the IAEA in Austria, January 2003.